Other substances

Doxycycline

A tetracycline antibiotic.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Doxycycline is a broad spectrum antibiotic inhibiting bacterial proteosynthesis (NCIt). It is listed in the World Health Organization
Model List of Essential Medicines.

Doxycycline on DrugBank
Doxycycline on PubChem
Doxycycline on Wikipedia

Marketed as

ORACEA; DOXYCYCLINE; VIBRAMYCIN; DOXYHEXAL; As doxycycline hyclate: ACTICLATE; ATRIDOX; DORYX; DOXY

C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities Preprint Case series	Patients		in combination with hydroxychloroquine	May/22/2020
Clinical Outcomes of Early Treatment With Doxycycline for 89 High-Risk COVID-19 Patients in Long-Term Care Facilities in New York Severe severity Small molecule Case series Moderate severity	Patients	1.90	Early treatment of moderate to severe COVID-19 high-risk patients is associated with decreased mortality and hospitalization and early clinical recovery. Sample size: 89. Dosage: 100 mg daily for 7 days.	Aug/11/2020
Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease Small molecule Case series	Patients (high risc)	3.18	Treatment resulted in mild course/clinical improvement in high-risc patients. Sample size: 4. Dosage: 100 mg or 200 mg for 5 to 14 days.	Sep/01/2020
In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2 Small molecule In vitro	Vero E6 cells; SARS-CoV-2 strain (IHUMI-3)	3.27	Doxycyklin manifests anti-SARS-CoV-2 activity in vitro at concentration which can be achieved by standard oral or intravenous dosing.	Oct/31/2020
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine... Small molecule Randomized controlled double-blind trial Moderate severity Mild severity	Mild to moderate COVID-19 patients	2.44	In combination with lopinavir and ritonavir. Shorter time to negative RT-PCR test was observed compared to standard care with azithromycin control. The average levels of CRP and IL-6 were lower and levels of IL-10 and TNF-α higher in the treatment group when compared to the control. Sample size: Combined with lopinavir and ritonavir (LPV/r): 124 (lower LPV/r dosing) + 129 (higher LPV/r dosing); 119 azithromycin-only control. Dosage: 100 mg twice a day.	Feb/09/2021
Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects ARDS Severe severity Small molecule Case series Moderate severity	Acute lung injury patients	3.41	Clinical and radiological improvement was observed in a series of patients with COVID-19 pneumonia after a sequential treatment with doxycycline on week 1 and doxycycline with colchicine on week 2. Sample size: 5. Dosage: 200 mg a day.	Mar/14/2021

AI-suggested references

Link	Publication date
Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2.	Oct/13/2021
Topical interferon in recurrent inflammatory macular edema following a cat bite.	May/15/2021
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.	Dec/02/2021
In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19.	May/16/2022
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)	Nov/17/2020
Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients	Nov/03/2020
Doxycycline as a potential partner of COVID-19 therapies	Jun/06/2020
Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity	Nov/28/2021
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Mo	Aug/28/2021
Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation.	May/04/2022
Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19.	Jun/24/2020
Tetracycline as an inhibitor to the SARS-CoV-2	Feb/22/2021
Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection	Apr/15/2020
Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2.	Jun/03/2020
Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations	Jul/09/2020
An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia	Sep/30/2021
Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.	Jun/14/2021
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.	Dec/02/2020
In Vitro Effects of Doxycycline on Replication of Feline Coronavirus.	Mar/07/2021
Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation	Dec/17/2020
Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19.	Sep/28/2020
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole	Jul/02/2020
Doxycycline in the Coronavirus Disease 2019 Therapy	Mar/06/2021
An ionophore breaks the multi-drug-resistance of Acinetobacter baumannii	Jul/06/2021
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial	May/14/2021
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.	Jul/27/2021
Multi-drug Treatment for COVID-19-induced Acute Respiratory Distress Syndrome	Feb/28/2022
Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?	May/18/2021
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches	Jul/05/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04591600	Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients	Completed	Phase 1\|Phase 2	Jul/01/2020	Oct/14/2020
Alternative id - IVM-DOX Interventions - Drug: Ivermectin and Doxycyline\|Drug: Standard of care Study type - Interventional Study results - No Results Available Locations - Akarkh Healt hdirectorate, Baghdad, Iraq Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 140 Age - 16 Years to 86 Years (Child, Adult, Older Adult) Outcome measures - Mortality rate\|Rate of progression disease\|Time to recovery
NCT04551755	Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19	Not yet recruiting	Phase 2	Sep/01/2020	Dec/01/2020
Alternative id - 31211062020 Interventions - Drug: Ivermectin and Doxycycline\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 188 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to outcome measure of fever (<100.40F)and cough\|Negative RT-PCR test on day 5 of treatment
NCT04715295	Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19	Recruiting	Phase 4	Oct/05/2020	Sep/05/2021
Alternative id - CNO0032020 Interventions - Drug: Doxycycline Tablets\|Drug: Rivaroxaban 15Mg Tab\|Combination Product: Hydroxychloroquine and Azithromycin Study type - Interventional Study results - No Results Available Locations - Yaounde Central Hospital, Yaounde, Centre, Cameroon Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 200 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Clinical\|Virological\|Symptom remission\|Hospitalisation\|Mortality\|Biological variables
NCT04349410	The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol	Completed	Phase 2\|Phase 3	Apr/11/2020	Sep/14/2020
Alternative id - FMTVDM2020 Interventions - Drug: Hydroxychloroquine, Azithromycin\|Drug: Hydroxychloroquine, Doxycycline\|Drug: Hydroxychloroquine, Clindamycin\|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.\|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.\|Drug: Remdesivir\|Drug: Tocilizumab\|Drug: Methylprednisolone\|Drug: Interferon-Alpha2B\|Drug: Losartan\|Drug: Convalescent Serum Study type - Interventional Study results - No Results Available Locations - FHHI-OI-Camelot; QME, Los Angeles, California, United States Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: Single (Investigator)\|Primary Purpose: Treatment Enrollment - 1800 Age - Child, Adult, Older Adult Outcome measures - Improvement in FMTVDM Measurement with nuclear imaging.\|Ventilator status\|Survival status
NCT04482686	Trial of Combination Therapy to Treat COVID-19 Infection	Active, not recruiting	Phase 1	Dec/09/2020	Jul/01/2022
Alternative id - PRG-049 Interventions - Drug: Ivermectin\|Drug: Doxycycline Hcl\|Dietary Supplement: Zinc\|Dietary Supplement: Vitamin D3\|Dietary Supplement: Vitamin C Study type - Interventional Study results - No Results Available Locations - ProgenaBiome, Ventura, California, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 31 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to Non-Infectivity by RT-PCR\|Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score)\|Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score)\|Efficacy of Treatment as measured by Titer\|Efficacy of Treatment as measured by RT-PCR\|Safety of Treatment as Measured by D-Dimer\|Safety of Treatment as Measured by Pro-Calcitonin\|Safety of Treatment as Measured by C-Reactive Protein\|Safety of Treatment as Measured by Ferritin\|Safety of Treatment as Measured by Liver Enzymes\|Safety of Treatment as Measured by Complete Blood Count\|Safety of Treatment as Measured by Electrolyte Levels\|Safety of Treatment as Measured by Treatment Related Adverse Events
NCT04371952	DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)	Not yet recruiting	Phase 3	Jun/01/2020	Dec/01/2020
Alternative id - RC20_0191 Interventions - Drug: Doxycycline\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - CHU Avicenne - APHP, Bobigny, France\|CHU Bordeaux, Bordeaux, France\|CHU Caen, Caen, France\|CHU Dijon, Dijon, France\|CHU Grenoble, Grenoble, France\|CHU Nantes, Nantes, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 330 Age - 46 Years and older (Adult, Older Adult) Outcome measures - Percentage of Patients with Clinical Respiratory Aggravation\|Percentage of patients hospitalized\|Percentage of patients requiring ventilatory assistance\|Positive SARS-CoV-2 PCR Test\|Duration of symptoms\|Duration of hospitalization\|Hospitalization intensive care or reanimation\|Duration of mechanical ventilatory assistance\|Percentage of deaths related to SARS-CoV-2\|AE / SAE in both arms
NCT04584567	OD-doxy-PNV-COVID-19 Old Drug " DOXY " for Prevention of New Virus " COVID-19 "	Completed	Phase 3	Nov/20/2020	Nov/01/2021
Alternative id - UR17DN05 Interventions - Drug: Doxycyclin Study type - Interventional Study results - No Results Available Locations - Military Hospital of Tunis, Tunis, Montfleury, Tunisia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Prevention Enrollment - 194 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - decreasing the number of cases infected with covid 19\|Measurement of the emergence of clincal symptoms of COVID 19\|the seroprevalence of SARS- CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving DOXY compared to those receiving placebo.
NCT04370782	Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting	Completed	Phase 4	Apr/28/2020	Sep/30/2020
Alternative id - 20-21 Interventions - Drug: Hydroxychloroquine\|Drug: Azithromycin\|Drug: Zinc Sulfate\|Drug: Doxycycline Study type - Interventional Study results - No Results Available Locations - St Francis Hospital, Roslyn, New York, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 18 Age - 30 Years and older (Adult, Older Adult) Outcome measures - Time to Resolution of Symptoms relative to baseline (day 1 of trial)\|Number of participants hospitalized and/or requiring repeat ER visits\|ICU Length of Stay\|Ventilator\|Severity of symptoms\|Number of participants with adverse events due to drug regimen\|Number of participants with QTc prolongation >500ms
NCT04729140	An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization	Recruiting	Phase 4	Dec/28/2020	Mar/28/2022
Alternative id - COVIVER-OUT PLUS Interventions - Drug: Ivermectin Tablets\|Drug: Doxycycline Tablets\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - MAX HEALTH, Subsero Health 2055 Wood Street, Suite 100, Sarasota, Florida, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 150 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Decreased admission rate to the hospital secondary to respiratory illness related to COVID-19\|Decrease in total duration of symptoms secondary to respiratory illness related to COVID-19\|Assessment of White Blood Cell Count\|Assessment of Hemoglobin level\|Assessment of Hematocrit level\|Assessment of Platelet Count\|Assessment of Sodium level\|Assessment of Potassium level\|Assessment of Chloride level\|Assessment of Carbon Dioxide level\|Assessment of Blood Urea Nitrogen level\|Assessment of Creatinine level\|Assessment of Calcium level\|Assessment of Glucose level\|Assessment of Total Bilirubin level\|Assessment of Total Protein level\|Assessment of Albumin level\|Assessment of Aspartate Aminotransferase level\|Assessment of Alanine Aminotransferase level\|Assessment of Alkaline Phosphatase level\|Assessment of Ferritin\|Assessment of D-dimer\|Assessment of Creatine Phosphokinase\|Assessment of C-Reactive Protein\|Assessment of Prothrombin Time and International Normalized Ratio\|Assessment of activated Partial Thromboplastin Time\|Assessment of Fibrinogen Activity\|Assessment of Interleukin 6 level\|Assessment of Interleukin 6 receptor level\|Assessment of Tumor Necrosis Factor Alpha level\|Assessment of Tumor Necrosis Factor Alpha Receptor level\|Mortality\|Measurement of Participants with Medication Side Effects\|Measurement of Participants with new onset Shortness of Breath or Changes in Shortness of Breath Severity\|Measurement of Participants Pulse Oximetry readings on room air\|Measurement of Participants with new onset Red Eyes or Changes in Red Eyes Severity\|Measurement of Participants with new onset Chills or Changes in Chills Severity\|Measurement of Participants with new onset Runny Nose or Changes in Runny Nose Severity\|Measurement of Participants with new onset Sore Throat or Changes in Sore Throat Severity\|Measurement of Participants with new onset Loss of Smell or Changes in Severity of in Loss of Smell\|Measurement of Participants with new onset Loss of Taste or Changes in Severity of Loss of Taste\|Measurement of Participants with new onset Body Aches or Body Pains or Changes in Body Aches or Body Pains Severity\|Measurement of Participants with new onset Diarrhea or Changes in Diarrhea Severity\|Measurement of Participants with new onset Headaches or Changes in Headaches Severity\|Measurement of Participants with new onset Anxiety or Changes in Anxiety Severity\|Measurement of Participants with new onset Fatigue or Changes in Fatigue Severity\|Measurement of Participants with new onset Trouble Concentrating or Changes in Trouble Concentrating Severity\|Measurement of Participants with new onset Cough or Changes in Cough Severity\|Measurement of Participants with new onset Vomiting or Changes in Vomiting Severity\|Measurement of Participants with new onset Nausea or Changes in Nausea Severity\|Measurement of Participants with new onset Feelings of Hopelessness or Changes in Feelings of Hopelessness severity\|Measurement of Participants with new onset feelings of Depression or Changes in feelings of Depression severity\|Measurement of Participants with new onset Fever or Changes in Fever Severity\|Measurement of Participants with new onset Moving Slowly or Changes in the Severity of Moving Slowly\|Measurement of Participants with new onset Speaking Slowly or Changes in the Severity of Speaking Slowly\|Measurement of Participants with new onset Feelings of Restlessness or Changes in the Severity of Feelings of Restlessness\|Measurement of Participants with new onset Thoughts of Better Off Being Dead or Changes in the Severity of Thoughts of Better Off Being Dead\|Measurement of Participants with new onset Thoughts of Hurting Yourself or Changes in the Severity of Thoughts of Hurting Yourself\|Measurement of Participants with new onset Loss of Interest in Doing Things or Changes in the Severity of Loss of Interest in Doing Things\|Measurement of Participants with new onset Loss of Pleasure in Doing Things or Changes in the Severity of Loss of Pleasure in Doing Things\|Measurement of Participants with new onset Trouble Falling Asleep or Changes in the Severity of Trouble Falling Asleep\|Measurement of Participants with new onset Trouble Staying Asleep or Changes in the Severity of Trouble Staying Asleep\|Measurement of Participants with new onset Unmentioned Negative Impacts of COVID 19 infection or Changes in the Severity of these Negative Impacts of COVID 19 infection
NCT04434144	A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh	Completed		May/02/2020	Jun/05/2020
Alternative id - 10000918 Interventions - Drug: Ivermectin + Doxycycline\|Drug: Hydroxychloroquine + Azithromycin Study type - Observational Study results - No Results Available Locations - Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh Study designs - Observational Model: Case-Only\|Time Perspective: Prospective Enrollment - 116 Age - 16 Years to 80 Years (Child, Adult, Older Adult) Outcome measures - Number of participants with "treatment success" determine by a negative RT PCR for COVID19.\|Number of participants with "adverse effects" determined by the existence of the pharmacological side effects of the particular drug during treatment.
NCT04407130	Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.	Completed	Phase 2	Jun/16/2020	Nov/20/2020
Alternative id - PR-20039 Interventions - Drug: Ivermectin + Doxycycline + Placebo\|Drug: Ivermectin + Placebo\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Icddr,B, Dhaka, Bangladesh Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 72 Age - 40 Years to 65 Years (Adult, Older Adult) Outcome measures - Virological clearance\|Remission of fever\|Remission of cough\|Patients requiring oxygen\|Patients failing to maintain SpO2 >93% despite oxygenation\|Number of days on oxygen support\|Duration of hospitalization\|All causes of mortality
NCT04523831	Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection	Completed	Phase 3	Jun/01/2020	Sep/10/2020
Alternative id - ERC-DMC/ECC/2020/117 Interventions - Drug: Ivermectin and Doxycycline\|Drug: Standard of care Study type - Interventional Study results - Has Results Locations - Dhaka Medical College, Dhaka, Bangladesh Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 400 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Number of Patients With Early Clinical Improvement\|Number of Participants With Late Clinical Recovery\|Number of Patients Having Clinical Deterioration.\|Number of Patients Remain Persistently Positive for RT-PCR of Covid-19
NCT04528927	Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia	Withdrawn	Phase 3	May/15/2020	Jul/15/2020
Alternative id - ECC2020-05 Interventions - Drug: HCQ\|Drug: Azithromycin\|Drug: Doxycycline\|Dietary Supplement: Zinc Study type - Interventional Study results - No Results Available Locations - Eshmoun Clinical Research Centre, Tunis, Tunisia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Evaluate the rate of patients cured at the end of the study.\|Evaluate the rate of patients are pauci-symptomatic at the end of the study.\|Evaluate the rate of patients with worsening clinical signs
NCT04433078	RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM	Withdrawn	Phase 2	Jun/22/2020	Apr/13/2021
Alternative id - The STORM Trial Interventions - Drug: Doxycycline\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Temple University Hospital, Philadelphia, Pennsylvania, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time Free of Either Hospitalization, Hypoxemia, ICU Admission or Death\|NP SARS-CoV-2 PCR\|SARS-CoV-2 Serum Quantitative Viral Load\|SARS-CoV-2 IgM/IgG Antibodies\|White Blood Cell Count (WBC)\|Absolute Lymphocyte Count (ALC)\|C-Reactive Protein (CRP)\|N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP)\|High Sensitivity Troponin I (hsTnT)\|Tumor Necrosis Factor Alpha (TNF-a)\|IL-1\|IL-1B\|IL-6

Export (.csv)